169 related articles for article (PubMed ID: 37511523)
41. Role of cited-1 and caspase-6 expression in HELLP syndrome.
Öcal E; Alkan Akalın S; Aşır F
Eur Rev Med Pharmacol Sci; 2023 Apr; 27(7):3082-3087. PubMed ID: 37070911
[TBL] [Abstract][Full Text] [Related]
42. Severe HELLP syndrome masquerading as thrombocytopenic thrombotic purpura: a case report.
Mousseaux C; Joly BS; Mohamadou I; Arrestier R; Hertig A; Rafat C
BMC Nephrol; 2020 May; 21(1):204. PubMed ID: 32471388
[TBL] [Abstract][Full Text] [Related]
43. Impaired cytotrophoblast cell-cell fusion is associated with reduced Syncytin and increased apoptosis in patients with placental dysfunction.
Langbein M; Strick R; Strissel PL; Vogt N; Parsch H; Beckmann MW; Schild RL
Mol Reprod Dev; 2008 Jan; 75(1):175-83. PubMed ID: 17546632
[TBL] [Abstract][Full Text] [Related]
44. Severe preeclampsia with and without HELLP differ with regard to placental pathology.
Vinnars MT; Wijnaendts LC; Westgren M; Bolte AC; Papadogiannakis N; Nasiell J
Hypertension; 2008 May; 51(5):1295-9. PubMed ID: 18362224
[TBL] [Abstract][Full Text] [Related]
45. Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity.
Taché V; LaCoursiere DY; Saleemuddin A; Parast MM
Hum Pathol; 2011 Sep; 42(9):1283-8. PubMed ID: 21334711
[TBL] [Abstract][Full Text] [Related]
46. Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome.
Strand S; Strand D; Seufert R; Mann A; Lotz J; Blessing M; Lahn M; Wunsch A; Broering DC; Hahn U; Grischke EM; Rogiers X; Otto G; Gores GJ; Galle PR
Gastroenterology; 2004 Mar; 126(3):849-58. PubMed ID: 14988839
[TBL] [Abstract][Full Text] [Related]
47. HELLP Syndrome-Holistic Insight into Pathophysiology.
Petca A; Miron BC; Pacu I; Dumitrașcu MC; Mehedințu C; Șandru F; Petca RC; Rotar IC
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208649
[TBL] [Abstract][Full Text] [Related]
48. Placental overexpression of transforming growth factor-beta3 in the HELLP syndrome.
Emanuelli M; Giannubilo SR; Landi B; Sartini D; Pierella F; Corradetti A; Tranquilli AL
Gynecol Obstet Invest; 2008; 65(1):1-5. PubMed ID: 17671384
[TBL] [Abstract][Full Text] [Related]
49. The role of hepatic sinusoidal obstruction in the pathogenesis of the hepatic involvement in HELLP syndrome: Exploring the literature.
von Salmuth V; van der Heiden Y; Bekkers I; van Runnard Heimel P; Spaanderman MA; Peeters LL; Koek GH
Pregnancy Hypertens; 2020 Jan; 19():37-43. PubMed ID: 31877439
[TBL] [Abstract][Full Text] [Related]
50. Circulating levels of thrombospondin-1 are decreased in HELLP syndrome.
Stenczer B; Molvarec A; Szabó G; Szarka A; Fügedi G; Szijártó J; Rigó J
Thromb Res; 2012 Apr; 129(4):470-3. PubMed ID: 22035632
[TBL] [Abstract][Full Text] [Related]
51. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction.
Herraiz I; Dröge LA; Gómez-Montes E; Henrich W; Galindo A; Verlohren S
Obstet Gynecol; 2014 Aug; 124(2 Pt 1):265-273. PubMed ID: 25004342
[TBL] [Abstract][Full Text] [Related]
52. Alteration of homocysteine catabolism in pre-eclampsia, HELLP syndrome and placental insufficiency.
Herrmann W; Hübner U; Koch I; Obeid R; Retzke U; Geisel J
Clin Chem Lab Med; 2004; 42(10):1109-16. PubMed ID: 15552268
[TBL] [Abstract][Full Text] [Related]
53. A clinicohistopathologic comparison between HELLP syndrome and severe preeclampsia.
Smulian J; Shen-Schwarz S; Scorza W; Kinzler W; Vintzileos A
J Matern Fetal Neonatal Med; 2004 Nov; 16(5):287-93. PubMed ID: 15621545
[TBL] [Abstract][Full Text] [Related]
54. Glutathione and glutathione-related enzymes in decidua and placenta of controls and women with pre-eclampsia.
Knapen MF; Peters WH; Mulder TP; Merkus HM; Jansen JB; Steegers EA
Placenta; 1999 Sep; 20(7):541-6. PubMed ID: 10452907
[TBL] [Abstract][Full Text] [Related]
55. Nuclear transcription factor-kappa beta-dependent ultrastructural alterations within the placenta and systemic inflammatory activation in pregnant patients with hemolysis, elevated liver functions and low thrombocyte count (HELLP) syndrome: a case-control study.
Simsek Y; Gul M; Celik O; Aydin NE; Arda Düz S; Celik E; Ozerol E; Özerol IH; Tanbek K
Hypertens Pregnancy; 2013 Aug; 32(3):281-91. PubMed ID: 23905607
[TBL] [Abstract][Full Text] [Related]
56. Expression of galectin-1, -3 (gal-1, gal-3) and the Thomsen-Friedenreich (TF) antigen in normal, IUGR, preeclamptic and HELLP placentas.
Jeschke U; Mayr D; Schiessl B; Mylonas I; Schulze S; Kuhn C; Friese K; Walzel H
Placenta; 2007; 28(11-12):1165-73. PubMed ID: 17664004
[TBL] [Abstract][Full Text] [Related]
57. Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia.
Krauss T; Kuhn W; Lakoma C; Augustin HG
Am J Obstet Gynecol; 1997 Aug; 177(2):443-9. PubMed ID: 9290466
[TBL] [Abstract][Full Text] [Related]
58. Hypertension in an Animal Model of HELLP Syndrome is Associated With Activation of Endothelin 1.
Morris R; Spencer SK; Kyle PB; Williams JM; Harris A; Owens MY; Wallace K
Reprod Sci; 2016 Jan; 23(1):42-50. PubMed ID: 26130680
[TBL] [Abstract][Full Text] [Related]
59. Maternal TLR4 and NOD2 gene variants, pro-inflammatory phenotype and susceptibility to early-onset preeclampsia and HELLP syndrome.
van Rijn BB; Franx A; Steegers EA; de Groot CJ; Bertina RM; Pasterkamp G; Voorbij HA; Bruinse HW; Roest M
PLoS One; 2008 Apr; 3(4):e1865. PubMed ID: 18382655
[TBL] [Abstract][Full Text] [Related]
60. Soluble fms-like tyrosine kinase 1 (sFlt-1): A novel biochemical marker for acute fatty liver of pregnancy.
Trottmann F; Raio L; Amylidi-Mohr S; Mosimann B; Jarquin Campos A; Messerli FH; Risch L; Baumann MU
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1876-1884. PubMed ID: 34157141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
